Several major eye drop recalls in 2026 have exposed millions of American consumers to potential eye infection risks — and a wave of class action lawsuits is already underway. The eye drop recall lawsuit 2026 landscape involves overlapping crises at K.C. Pharmaceuticals, Alcon Research LLC, Lupin Pharmaceuticals, and other manufacturers, affecting products sold at CVS, Walgreens, Kroger, Publix, and dozens of other national retailers. If you used recalled eye drops this year, here is everything you need to know about the recalls, the litigation, and your legal options.
Multiple Recalls, One Alarming Pattern: What Happened in 2026
The first major recall of 2026 came on March 3, when K.C. Pharmaceuticals of Pomona, California, voluntarily recalled 3,111,072 bottles of over-the-counter eye drops due to a lack of assurance of sterility. The FDA classified this as a Class II recall, meaning the products may cause temporary or medically reversible adverse health consequences. Eight distinct product lines were pulled from shelves, including Dry Eye Relief, Artificial Tears Sterile Lubricant, Sterile Eye Drops Original Formula, Sterile Eye Drops Redness Lubricant, Eye Drops Advanced Relief, Ultra Lubricating Eye Drops, Sterile Eye Drops AC, and Sterile Eye Drops Soothing Tears.
Then, in April 2026, Alcon Research LLC separately recalled all unexpired lots of its Systane Night Gel Comforting Dry Eye Relief and GenTeal Tears Lubricant Eye Gel products — also citing lack of assurance of sterility. The contamination source was traced to Excelvision Fareva, a contract manufacturing facility in France. Additional brands manufactured at the same facility — including Harrow Eye LLC’s Freshkote PF, OASIS Medical’s Oasis Tears PF, Scope Health’s Optase Dry Eye Intense, and Thea Pharma’s Ivizia Lubricant Eye Drops — were also implicated.
In July 2026, the recalls expanded further when Lupin Pharmaceuticals initiated a voluntary recall of approximately 2.5 million bottles of prednisoLONE Acetate Ophthalmic Suspension on July 10, 2026, due to foreign substance contamination. The Clear Eyes Maximum Itchy Eye Relief recall was subsequently updated to a Class II classification on August 14, 2026, broadening the scope of products under federal scrutiny. The eye drop recall lawsuit 2026 filings that followed allege these were not isolated manufacturing failures but the predictable result of years of ignored warning signs.
The FDA’s Documented Warning History: Repeated Red Flags Before the Recalls
What makes these recalls especially troubling for mass tort attorneys and consumer advocates is the documented pattern of prior FDA intervention at multiple manufacturers. K.C. Pharmaceuticals had already been flagged by the FDA following a 2023 inspection, which resulted in a warning letter directing the company to change sterility protocols and consult outside experts. The 2026 recall strongly suggests those quality control improvements were never fully implemented — making this the second time since 2023 that federal regulators identified sterility concerns at the same Pomona facility. The FDA issued K.C. Pharmaceuticals a new warning letter on August 12, 2026, following an inspection of its facility earlier that year, underscoring the agency’s continued concern about conditions at the site.
The regulatory history at Excelvision Fareva is even more extensive. Mold contamination on aseptic filling lines at the French facility dates back to 2022, with documented presence of Penicillium citrinum, Fusarium oxysporum, and Aspergillus species. The FDA issued a formal Warning Letter to Excelvision in May 2025 following inspections in November 2024 and July 2023, identifying violations in sterility and aseptic processing. When the FDA re-inspected Excelvision in January 2026, it found 11 new citations, six of which were directly related to aseptic processing and microbiological contamination. In late April 2026, the FDA placed Excelvision on its import alert list, effectively blocking new shipments of the facility’s products from entering the United States.
Why Non-Sterile Eye Drops Are Dangerous: The Medical Reality
The eyes are among the most sensitive and infection-vulnerable organs in the human body. Unlike the skin or the gastrointestinal tract, the ocular surface lacks the robust microbial defenses that protect other tissues. When a contaminated product is introduced directly onto the eye — particularly in patients who are immunocompromised, elderly, or recovering from eye surgery — the consequences can be swift and severe.
Bacterial and fungal eye infections can progress from initial irritation to corneal ulceration within days. In the most serious cases, contaminated eye drops have been linked to endophthalmitis, a devastating intraocular infection that can cause permanent vision loss or blindness. The specific mold species identified at Excelvision Fareva — including Fusarium oxysporum and Aspergillus — are well-documented causes of fungal keratitis, a corneal infection notoriously difficult to treat and frequently associated with long-term visual impairment. Patients who used recalled products and subsequently developed eye pain, redness, blurred vision, discharge, or sensitivity to light are encouraged to seek immediate medical evaluation and preserve all documentation of their product use and symptoms.
Eye Drop Recall Data at a Glance: 2026 Key Statistics
- March 3, 2026: K.C. Pharmaceuticals recalls 3,111,072 bottles — Class II, lack of sterility assurance
- April 2026: Alcon Research LLC recalls all unexpired lots of Systane Night Gel and GenTeal Tears — lack of sterility assurance; multiple additional brands from same French facility also recalled
- July 10, 2026: Lupin Pharmaceuticals recalls approximately 2.5 million bottles of prednisoLONE Acetate Ophthalmic Suspension — foreign substance contamination
- August 14, 2026: Clear Eyes Maximum Itchy Eye Relief recall updated to Class II classification
- August 12, 2026: FDA issues new warning letter to K.C. Pharmaceuticals following facility inspection
- Excelvision Fareva: 11 new FDA citations identified in January 2026 re-inspection; facility placed on import alert in late April 2026
- Retailers affected: CVS, Walgreens, Kroger, Publix, Walmart, Target, and dozens of others nationwide
- Settlement status: No settlements, verdicts, or settlement benchmarks have been established yet for 2026 eye drop recalls; litigation is in early stages
The Class Action Lawsuits Filed in 2026
Litigation over the 2026 eye drop recalls is moving on multiple fronts. A proposed class action lawsuit alleges that Alcon’s Systane and GenTeal Tears products were falsely labeled as sterile despite manufacturing contamination that culminated in the April 2026 recall. The complaint alleges that Alcon knew or should have known about the conditions at Excelvision Fareva — given the facility’s well-documented history of mold contamination dating back to 2022 — yet continued to market and sell the products as sterile and safe for direct ocular use.
Plaintiffs in these cases are pursuing claims under theories including strict products liability, negligence, breach of express and implied warranty, and violations of state consumer protection statutes. The false labeling allegations are particularly significant because they support claims even for consumers who did not suffer a documented infection, arguing that they paid a premium for a product represented as sterile that was not in fact sterile. Additional lawsuits related to the K.C. Pharmaceuticals recall and the Lupin prednisoLONE recall are expected as attorneys continue to investigate the scope of consumer harm.
It is important to note that no settlements, verdicts, or settlement benchmarks have been established yet for the 2026 eye drop recalls. The litigation is in its early stages, and the ultimate value of individual claims will depend on the nature and severity of each plaintiff’s injuries, documented product use, and medical records. Consumers who believe they were harmed should consult with a qualified mass tort attorney as soon as possible to preserve their rights.
Who Is Affected: Retailers, Products, and Consumer Exposure
The breadth of the 2026 eye drop recalls is striking. K.C. Pharmaceuticals products were sold under multiple private-label and store-brand names at major national retailers including CVS, Walgreens, Kroger, Publix, Walmart, and Target, among others. Because these products were positioned as affordable, everyday alternatives to name-brand lubricating drops, they reached a particularly wide consumer base — including patients managing chronic dry eye conditions who used the products multiple times daily.
The Alcon recall affects consumers who purchased Systane Night Gel and GenTeal Tears, two products commonly recommended by ophthalmologists and optometrists for moderate to severe dry eye relief. The same Excelvision Fareva manufacturing facility also produced Freshkote PF, Oasis Tears PF, Optase Dry Eye Intense, and Ivizia Lubricant Eye Drops, meaning patients who relied on any of these brands for post-surgical care or chronic eye disease management may also have been exposed. The Lupin prednisoLONE Acetate Ophthalmic Suspension recall, covering approximately 2.5 million bottles, affects a prescription steroid eye drop commonly used following eye surgery and for inflammatory eye conditions — a population that may be especially vulnerable to infection risk.
Action Guide: What to Do If You Used a Recalled Eye Drop Product
- Stop using the product immediately. Do not continue using any eye drop product identified in the 2026 recalls, even if it appears normal and you have not yet experienced symptoms.
- Preserve the product and packaging. Keep the bottle, box, lot number, and any receipts or purchase records. This documentation is critical evidence in any future legal claim.
- Seek medical evaluation. If you have experienced any eye symptoms — including redness, pain, discharge, blurred vision, or light sensitivity — see an ophthalmologist promptly. Obtain copies of all medical records related to your eye health from 2026 forward.
- Document your purchase and use history. Note where you purchased the product, approximately when you began using it, and how frequently you used it. Pharmacy purchase histories and loyalty program records can help reconstruct this information.
- Consult a mass tort attorney. The statute of limitations for product liability claims varies by state, typically ranging from one to three years from the date of injury or discovery of harm. An attorney experienced in pharmaceutical mass torts can evaluate your claim at no upfront cost and advise you on your options.
- Report your experience to the FDA. Consumer reports submitted through the FDA’s MedWatch program help regulators track the scope of harm and can strengthen the evidentiary record in class action proceedings.
Frequently Asked Questions About the Eye Drop Recall Lawsuit 2026
What products are included in the 2026 eye drop recalls?
As of mid-2026, recalled eye drop products include K.C. Pharmaceuticals’ eight OTC product lines (recalled March 3, 2026), Alcon’s Systane Night Gel and GenTeal Tears (recalled April 2026), several additional products manufactured at Excelvision Fareva in France (including Freshkote PF, Oasis Tears PF, Optase Dry Eye Intense, and Ivizia), Lupin Pharmaceuticals’ prednisoLONE Acetate Ophthalmic Suspension (recalled July 10, 2026), and Clear Eyes Maximum Itchy Eye Relief (Class II recall classification updated August 14, 2026). Consumers should check the FDA’s recall database regularly, as the list of affected products may continue to expand.
Do I need to have a confirmed eye infection to join an eye drop recall lawsuit in 2026?
Not necessarily. While consumers who suffered documented eye infections, corneal injuries, or vision loss may have the strongest individual claims and the highest potential damages, class action lawsuits can also include plaintiffs who purchased recalled products but did not develop infections. The false labeling theory — alleging that products were sold as sterile when they were not — supports claims based on economic harm, meaning consumers who paid for a product that did not meet its advertised standard may be eligible to participate regardless of whether a physical injury occurred. An attorney can help you determine which legal theory best fits your circumstances.
Why were Alcon’s Systane Night Gel and GenTeal Tears recalled in 2026?
Alcon recalled Systane Night Gel and GenTeal Tears in April 2026 due to lack of assurance of sterility. The contamination was traced to Excelvision Fareva, a contract manufacturer in France that had a documented history of mold contamination on its aseptic filling lines dating back to 2022. The FDA had issued Excelvision a formal Warning Letter in May 2025 and found 11 new violations during a January 2026 re-inspection, including six related to aseptic processing and microbiological contamination. A proposed class action alleges that Alcon falsely labeled these products as sterile despite knowledge of ongoing manufacturing deficiencies at the facility.
What lawsuits have been filed over the 2026 eye drop recalls?
As of 2026, a proposed class action lawsuit has been filed alleging that Systane and GenTeal Tears products were falsely labeled as sterile despite manufacturing contamination. Additional litigation related to the K.C. Pharmaceuticals and Lupin Pharmaceuticals recalls is expected as investigations progress. No settlements, verdicts, or settlement benchmarks have been established yet. The cases are in early stages, and consumers who believe they were harmed should consult an attorney promptly to understand their rights and preserve evidence before statutes of limitations expire.
How long do I have to file an eye drop recall lawsuit claim in 2026?
The deadline to file a product liability lawsuit — known as the statute of limitations — varies by state, but most states allow between one and three years from the date of injury or from the date you discovered, or reasonably should have discovered, that a product caused your harm. Because the major 2026 recalls began in March and continued through the summer of 2026, the clock is already running for many consumers. Do not wait to seek legal advice. A mass tort attorney can evaluate your potential claim at no cost and help ensure you do not miss your filing window.
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.